Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab ± Tremelimumab in Pediatric Advanced Malignancies
2023-510424-68-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tiragolumab in Nonhematologic neoplasms and hematopoietic malignancies (2 arms), sponsored by AstraZeneca. Primary endpoints: Adult equivalent exposure/MTD of durvalumab in combination with tremelimumab and durvalumab monotherapy, Safety and tolerability at adult equivalent exposure/MTD and 2 more. Planned start Jun 2024; status: authorised.
02
Drugs
durvalumabtiragolumab
03
Conditions
Nonhematologic neoplasmshematopoietic malignancies
Beyond the preview
Go deeper on 2023-510424-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510424-68-00.